rasagiline has been researched along with Multiple System Atrophy Syndrome in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abler, V; Goebel, G; Krismer, F; Papapetropoulos, S; Poewe, W; Schocke, M; Seppi, K; Wenning, GK | 1 |
| Galpern, WR | 1 |
| Barone, P; Eyal, E; Fitzer-Attas, CJ; Giladi, N; Gilman, S; Low, PA; Poewe, W; Rascol, O; Sampaio, C; Seppi, K; Wenning, GK | 1 |
| Abler, V; Krismer, F; Papapetropoulos, S; Poewe, W; Seppi, K; Wenning, GK | 1 |
| Poewe, W; Stefanova, N; Wenning, GK | 1 |
3 trial(s) available for rasagiline and Multiple System Atrophy Syndrome
| Article | Year |
|---|---|
Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy.
Topics: Aged; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Neuroprotective Agents; Prospective Studies | 2019 |
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.
Topics: Aged; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Multiple System Atrophy; Neuroprotective Agents; Parkinsonian Disorders; Treatment Outcome | 2015 |
Minimally clinically important decline in the parkinsonian variant of multiple system atrophy.
Topics: Aged; Female; Humans; Indans; Male; Middle Aged; Minimal Clinically Important Difference; Multiple System Atrophy; Neuroprotective Agents; Parkinsonian Disorders; Severity of Illness Index | 2016 |
2 other study(ies) available for rasagiline and Multiple System Atrophy Syndrome
| Article | Year |
|---|---|
Clinical trials for multiple system atrophy.
Topics: Female; Humans; Indans; Male; Multiple System Atrophy; Neuroprotective Agents; Parkinsonian Disorders | 2015 |
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Response Relationship, Drug; Indans; Mice; Mice, Transgenic; Motor Activity; Multiple System Atrophy; Myelin Proteolipid Protein; Neurons; Neuroprotective Agents; Nitro Compounds; Propionates; Psychomotor Performance; Tyrosine 3-Monooxygenase | 2008 |